The European angle, stated honestly first
The material behind this piece contains no EU regulatory development: no EMA decision, no EU AI rule, no European policy text. We will not invent one. The European threads that are verifiable are narrower. One is a Stockholm-listed royalty earner. Another is a Swiss company filling a dealmaking post. A third is a London-and-Florida oncology developer. They sit in a global sector whose clinical news was steady while the AI-finance backdrop weakened.1
Sweden: a royalty that tells you whether a drug is really selling
BioArctic AB, headquartered in Stockholm, is partnered with Eisai on Leqembi.2 Eisai's preliminary global Leqembi sales for the second quarter of 2026 were JPY 29.3 billion. That produced a royalty to BioArctic of SEK 179 million, up about 10 percent on the same quarter of 2025.2
The headline growth understates the underlying trend. The 2025 quarter included a one-time stockpiling effect in China of around JPY 5.3 billion. BioArctic says that excluding it, royalty revenues grew approximately 43 percent year over year.2 The company is the speaker on both figures, and both come from its own release. They are company-reported, not independently audited.
The clinical headline: Vor Bio's TELIGAN results
On October 22, 2026, Vor Bio announced final two-year Phase 3 results for telitacicept in IgA nephropathy, a kidney disease. The company reports an annualized eGFR slope of -0.6 against -5.7 mL/min/1.73 m²/year for placebo. That is a treatment difference of 5.1 (p<0.001). It also reports 89% and 81% reductions in the risk of confirmed 30% and 40% eGFR declines, with proteinuria reductions sustained through 104 weeks.1
This is a company press release, not a peer-reviewed paper or a regulator's finding. Its source category carries a measured reliability of 54% of 6,613 checked claims holding up.1 That is a middling record, so treat the numbers as the sponsor's account until a journal or regulator confirms them.
Incyte: the verified balance sheet
Incyte is the one company here where we hold fidelity-checked SEC-filing numbers. Its reported cash was $3.28 billion at Q3 2026, against $2.46 billion at Q3 2025.3 The path in between was uneven: $3.46 billion at Q1 2026 and $3.98 billion at Q2 2026.3 The wider history is much more volatile. Cash was $987 million at Q2 2024 and $1.69 billion at fiscal year-end 2024, then $3.10 billion at fiscal year-end 2025.3 So today's cash pile is more than three times the Q2 2024 low.
Cost of revenue, a rough gauge of how much it costs to deliver what the company sells, rose from $99.0 million in Q3 2025 to $108.7 million in Q3 2026.4 Over the full years it rose from $255.0 million in fiscal 2023 to $372.1 million in fiscal 2025.4 Capital expenditure was $48.7 million in both fiscal 2024 and fiscal 2025.5 The two years carry an identical figure, which is plausible but unusual enough that we flag it.
The dossier links Incyte to pemigatinib, a ruxolitinib phosphate cream, a PD-1-resistant head and neck cancer programme and a licensing deal with Dermavon Holdings Limited. It contains no verified detail on the ESMO pancreatic data. We therefore say nothing about those results beyond noting that they were part of the period's clinical flow.1
Pipeline timelines: promises, not results
Several companies gave timelines in this period. Each is a statement of intent by the company, not an outcome.
- Ernexa Therapeutics says it remains on schedule to submit its IND application for ERNA-101 in the third quarter of 2026, with a first-in-human Phase 1 trial anticipated in the fourth quarter.6
- Prelude Therapeutics expected an IND submission for PRT13722 by mid-2026 and a Phase 1 start in ER-positive breast cancer in the second half of 2026.7
- Akari Therapeutics, listed in London and Tampa, plans Phase 1 development of AKTX-101 in mid-2027. Its CEO's line is that ADC-refractory patients are "a significant, growing unmet need" and an exclusive opportunity for its novel payload.8
The Ernexa and Prelude items come from sources with weaker records. The roundup of Ernexa and others has a measured reliability of 35% of 3,660 checked claims holding up.6 We could not confirm in this material whether the Q3 and mid-2026 filings actually happened. Check the companies' own filings for that.
On the hiring side, Idorsia, the Swiss company, appointed Begoña Carreño-Gómez as Chief Business Development Officer and Executive Committee member, effective November 1, 2026.9 That is a fact about a dealmaking role being filled. It is not evidence of a deal.
AI-bio: early, and the sourcing is thin
Radical Numerics says AI-designed viruses have treated its first patient, with an experimental treatment aimed at drug-resistant E. coli.10 That is a company claim relayed in a newsletter. Its source carries a measured reliability of 6% of 16 checked claims holding up, a very small sample with a very poor result.10 We treat it as an unverified marker of direction, not as proof that the method works.
The same caution applies to Generation Lab, which says its treatment "blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism and restores health and youth to multiple tissues."11 A company fact sheet makes that claim. MIT Technology Review's headline on it is that the startup "claims" to have found a drug. The outlet's measured reliability here is 6% of 16 checked claims.11 We found no clinical evidence in the dossier supporting it.
The backdrop: where the money comes from
On October 30, 2026, a $1 trillion tech selloff deepened fears of an AI bubble, as big AI bills and weak earnings spooked investors. The Nasdaq 100 had its worst day since June.12 A trillion dollars is a number a saver can feel. Anyone who holds a global or US index fund, which typically has heavy technology weighting, will have seen it in their statement. The dossier does not give the actual weighting, so we cannot say how much.
The next day, October 31, OpenAI cut its funding target by $10 billion.13 On November 1, Binance users withdrew $3.6 billion when the exchange reopened after a hack.14 The entity graph connects Binance to Mastercard and Changpeng Zhao, but nothing in it ties these events to biotech.
What Via News's analysis suggests
Our narrative tracker labels this theme a divergence, with mixed sentiment: clinical progress steady, AI-finance sentiment weaker. That is our analysis, not an external finding. The data supports a modest version of it. Incyte's cash is rising and BioArctic's royalty is growing. Neither depends on AI funding. By contrast, the AI-designed-therapeutics stories rest on the weakest sources in the material. Companies at that early stage are the ones that would feel a tighter funding market first. The dossier contains no figure on AI-biotech fundraising, so that remains a question, not a finding.
What to watch
- Whether Vor Bio's TELIGAN results appear in a peer-reviewed journal or a regulatory filing, which would upgrade them from company-reported.
- Whether Ernexa's ERNA-101 Phase 1 begins in the fourth quarter as guided.
- BioArctic's next royalty figure, now that the China stockpiling comparison has passed.
- Incyte's next SEC filing, to see whether cash holds near $3.3 billion as costs of revenue climb.
- Any actual European regulatory action touching these companies. We found none in this period.